EN DE
Watch Werewolf Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Werewolf Therapeutics Inc (HOWL) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Werewolf Therapeutics Inc stock $0.85, price $0.99, that is 14.0% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US95075A1079

WT Werewolf Therapeutics Inc logo Thin data Nov 17, 2026

Werewolf Therapeutics Inc

HOWL · US

Expensive (fair value 14% below the price) and weak company.

Get notified free when this changes
Quality 42/100 
Mixed vs. peers (4/8) 
Insiders sold $456,119 (6M) 
Fair value $0.8523 · Overvalued 
Weak Growth (revenue 3y −23.1 %/yr in USD) 
Loss-making · -164.8% net margin (TTM) 
Negative free cash flow 
Narrow moat 3/100 · thin data
Thin data 
Estimate
Watch Werewolf Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.83 $0.3080 Fair Value $0.8523 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.3080 – $18.83 · fair‑value band $0.6392 – $1.07 · the $0.9908 price screens above the $0.8523 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Werewolf Therapeutics in your weekly email

Every Wednesday you see whether Werewolf Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions.

Show moreShow less

The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma.

The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.

In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer.

Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Stock analysis

Werewolf Therapeutics Inc (HOWL) currently trades at $0.9908, while our estimate is $0.8523, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.6392 (bear) to $1.07 (bull), the price of $0.9908 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Werewolf Therapeutics Inc reported revenue of $0 in FY2025 versus $4.1M in FY2021. Reported net income was −$60.8M in FY2025.

Key figures

Market cap $48.2M Micro · P/S ratio 2.27 · EPS (TTM) $−0.7300 · Return on equity −120% · Return on assets (EBIT) −46.3% (5-year average) · Operating margin −122% · Revenue (TTM) $21.0M · Free cash flow −$60.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 222% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −14%, HOWL screens richer than that median.

Fair Value

Bear $0.6392 Fair Value $0.8523 Bull $1.07
Price $0.9908 · Downside -14.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 66
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 80
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 64
Distance to the 52-week high, does not count
New shares 21
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $456,119 and none bought.

  • SaleLuke EvninDirector27× since Nov 17, 2025: 3,552,501 shares, avg. $0.6415$2.3MJul 7, 202610b5-1 plan
  • SaleRA CAPITAL MANAGEMENT, L.P.10% owner3× since May 8, 2026: 1,430,914 shares, avg. $0.4964$710,365Jun 17, 2026
  • SalePeter Kolchinsky10% owner678,226 shares at $0.3739$253,569Jun 11, 2026
  • SaleMPM BioImpact LLCFormer 10% Owner199,732 shares at $0.9176$183,275Dec 4, 202510b5-1 plan
  • SaleMPM BioVentures 2014 (B), L.P.Former 10% Owner199,732 shares at $0.9176$183,275Dec 4, 202510b5-1 plan
  • SaleUBS Oncology Impact Fund L.P.10% owner141,927 shares at $0.9643$136,855Dec 1, 202510b5-1 plan
  • SaleMPM Asset Management Investors BV2014 LLC10% owner141,927 shares at $0.9643$136,855Dec 1, 202510b5-1 plan
  • SaleMPM Oncology Innovations Fund GP LLC10% owner3× since Nov 17, 2025: 412,830 shares, avg. $0.9245$381,672Nov 25, 202510b5-1 plan
  • SaleMPM BioVentures 2014 GP LLC10% owner195,666 shares at $0.9176$179,551Nov 25, 202510b5-1 plan
  • SaleMPM BioVentures 2014 LLC10% owner2× since Nov 17, 2025: 217,164 shares, avg. $0.9307$202,121Nov 20, 202510b5-1 plan

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−90.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,207.5% (2021) → −3,904.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HOWL screens overvalued: fair value 14% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Werewolf Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −14.0% · Above median
Profitability
Return on assets −87.6% · Bottom 25%
Net margin (12 months) −164.8% · Bottom 25%
Operating margin (12 months) −121.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.94× · Cheaper than median
P/S (12 months) 2.29× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs HOWL
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs HOWL
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs HOWL
argenx SE ARGX $950.95 $908.40 −4% vs HOWL
CSL Limited CSL A$199.55 A$186.49 −7% vs HOWL
Moderna, Inc MRNA $215.27 $135.64 −37% vs HOWL
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs HOWL
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs HOWL
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs HOWL
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs HOWL

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Werewolf Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Werewolf Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/HOWL

Frequently asked questions

Is Werewolf Therapeutics Inc (HOWL) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $0.8523 versus a price of $0.9908, about 14% lower (overvalued).
What is the fair value of HOWL?
Our estimate for Werewolf Therapeutics Inc is $0.8523 (as of Nov 17, 2026), built from audited fundamentals. The current price: $0.9908.
What is the quality score of HOWL?
Werewolf Therapeutics Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Werewolf Therapeutics Inc (HOWL)?
Our calculated price target is the estimate of $0.8523 (as of Nov 17, 2026). Cautious scenario $0.6392, optimistic scenario $1.07. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Werewolf Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $0.8523, about 14% lower versus a price of $0.9908 (overvalued). Cautious scenario $0.6392, optimistic scenario $1.07. The calculation is refreshed regularly with new filings.
What is the revenue of Werewolf Therapeutics Inc (HOWL)?
Werewolf Therapeutics Inc reported trailing-twelve-month revenue of about $21.0M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Werewolf Therapeutics Inc (HOWL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Werewolf Therapeutics Inc it is $0.8523 per share (as of Nov 17, 2026), against a price of $0.9908.
Is Werewolf Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, HOWL trades above its calculated fair value: price $0.9908, fair value $0.8523, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HOWL?
No. The price is what the market pays today ($0.9908); the fair value is what the company's own numbers justify ($0.8523). For Werewolf Therapeutics Inc the two are $0.1385 per share apart. That gap is exactly why we show both numbers side by side.
How much is Werewolf Therapeutics Inc worth?
The market values Werewolf Therapeutics Inc at about $48.2M (market capitalisation, as of Nov 17, 2026). Per share that is $0.9908; our models calculate a fair value of $0.8523 per share.
What do the bullish and bearish scenarios say about HOWL?
Our models span a range for Werewolf Therapeutics Inc: cautious scenario $0.6392, base $0.8523, optimistic $1.07 per share (as of Nov 17, 2026, price $0.9908). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Werewolf Therapeutics Inc (HOWL)?
Balance-sheet figures for Werewolf Therapeutics Inc (as of Nov 17, 2026): return on equity −119.9%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is HOWL from its 52-week high?
Werewolf Therapeutics Inc trades at $0.9908, about 10% below its 52-week high of $1.10 and 222% above the low of $0.3080 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8523 is for.
Which stocks are comparable to Werewolf Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Werewolf Therapeutics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $0.9908, calculated fair value $0.8523 (−14%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Werewolf Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Werewolf Therapeutics Inc (HOWL)?
The closing price on Nov 16, 2026 was $0.9908. Our estimate is $0.8523, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Werewolf Therapeutics Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Werewolf Therapeutics Inc

How large is the market capitalisation of Werewolf Therapeutics Inc (HOWL)?
The market capitalisation of Werewolf Therapeutics Inc is $48.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Werewolf Therapeutics Inc (HOWL)?
The price-to-sales ratio of Werewolf Therapeutics Inc is 2.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Werewolf Therapeutics Inc (HOWL)?
Earnings per share at Werewolf Therapeutics Inc are $−0.7300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Werewolf Therapeutics Inc (HOWL)?
The return on equity (ROE) of Werewolf Therapeutics Inc is −120% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Werewolf Therapeutics Inc (HOWL)?
On an EBIT basis the return on assets of Werewolf Therapeutics Inc is −46.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Werewolf Therapeutics Inc (HOWL)?
The operating margin of Werewolf Therapeutics Inc is −122% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Werewolf Therapeutics Inc (HOWL) generate?
The free cash flow of Werewolf Therapeutics Inc is −$60.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Werewolf Therapeutics Inc (HOWL) hold?
Werewolf Therapeutics Inc holds more cash than debt, $48.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Werewolf Therapeutics Inc in the live analysis

One click puts Werewolf Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.